| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3292437 | Gastroenterology | 2013 | 10 Pages |
Abstract
In this phase 2 trial, administration of 25 or 50 mg OCA for 6 weeks was well tolerated, increased insulin sensitivity, and reduced markers of liver inflammation and fibrosis in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Longer and larger studies are warranted. ClinicalTrials.gov, Number: NCT00501592.
Keywords
NAFLDGIRFGFALTFXROCA7α-hydroxy-4-cholesten-3-onefarnesoid X receptorASTAspartate aminotransferaseAlanine aminotransferasenonalcoholic steatohepatitisobeticholic acidBile acidNonalcoholic fatty liver diseaseTreatmentMetabolic syndromefibroblast growth factorObesityglucose infusion rateNash Clinical trial
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Sunder Mudaliar, Robert R. Henry, Arun J. Sanyal, Linda Morrow, Hanns-Ulrich Marschall, Mark Kipnes, Luciano Adorini, Cathi I. Sciacca, Paul Clopton, Erin Castelloe, Paul Dillon, Mark Pruzanski, David Shapiro,